CELLECTRA™-5P

DEVICE3 trials

Sponsors

Inovio Pharmaceuticals

Conditions

Cervical CancerCervical Intraepithelial NeoplasiaHead and Neck Squamous Cell Cancer

Phase 1

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

CompletedNCT02163057

Inovio PharmaceuticalsHead and Neck Squamous Cell Cancer

Start: 2014-08-13End: 2017-01-23Updated: 2021-01-22

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

CompletedNCT02172911

Inovio PharmaceuticalsCervical Cancer

Start: 2014-06-06End: 2017-09-07Updated: 2021-02-21

Phase 2

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

CompletedNCT01304524

Inovio PharmaceuticalsCervical Intraepithelial Neoplasia

Start: 2011-04-30End: 2015-04-30Updated: 2018-09-07

Related Papers

A phase 1/2A trial of synthetic DNA vaccine immunotherapy targeting HPV-16 and -18 after chemoradiation for cervical cancer.

Journal of Clinical Oncology2018-05-204 citations

Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa).

Journal of Clinical Oncology2017-05-208 citations

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

2015-09-17512 citations

DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial

Journal for ImmunoTherapy of Cancer2014-11-064 citations